CCA
SPRY icon

Cygnus Capital Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Cygnus Capital Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,556
Closed -$123 – 178
2025
Q4 		$123 Buy
+10,556
New +$103K 0.09% 56

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Cygnus Capital Advisors's SPRY Position: Q1 2026 in Review

Cygnus Capital Advisors sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 10,556 shares — an estimated $123 sold.

Cygnus Capital Advisors first reported a position in SPRY in Q4 2025 and held it in 1 quarter. The position peaked at $123 in Q4 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Cygnus Capital Advisors reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 10,556 ARS Pharmaceuticals shares in Q1 2026, an estimated $123.
  • Cygnus Capital Advisors first reported a position in ARS Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Cygnus Capital Advisors's ARS Pharmaceuticals position peaked at $123 in Q4 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.